To the Editor: The two most common forms of diabetes that have been classified are type 1 diabetes and type 2 diabetes. Type 1 diabetes is characterised by infiltration of the pancreas by autoreactive T cells and autoimmune destruction of pancreatic beta cells, leading to a complete loss of insulin production, whereas type 2 diabetes is associated with the gradual increase of insulin insensitivity in tissues leading to hyperglycaemia and beta cell failure. However, it has been suggested that type 1 diabetes and type 2 diabetes may share a common genetic aetiology [1] . For example, the accelerator hypothesis suggests that type 1 diabetes and type 2 diabetes are the same disease of hyperglycaemiainduced beta cell damage but that type 1 diabetes has the added effect of autoimmunity [1] .
One way of testing the hypothesis that there is a common causal pathway between type 1 and type 2 diabetes is to analyse a type 2 diabetes gene with a large effect in a large type 1 diabetes sample. Until very recently [2] this has not been possible, as no such locus has emerged from type 2 diabetes genetics studies. Recently, however, the transcription-factor-7-like 2 (TCF7L2) gene region on chromosome 10q25.2 has been found to contribute substantially to the risk of type 2 diabetes with convincing statistical support (relative risk [RR]=0.67; p=2.1×10 −9 for the 0 allele of the microsatellite marker DG10S478) [2] . This study was carried out in three different populations: Icelandic, Danish and white American. Two single nucleotide polymorphisms (SNPs) were also genotyped in this study: rs12255372 (G>T, minor allele frequency [MAF] 0.36 in control subjects) and rs7903146 (C>T, MAF=0.28 in control subjects). rs12255372 was found to be in high linkage disequilibrium (LD) with DG10S478 (r 2 =0.95 for the major G allele of the SNP with the 0 allele of the microsatellite marker). rs7903146 was in lower LD with the DG10S478 (r 2 =0.75): for the minor allele (T) of this SNP the authors obtained odds ratios (ORs) of 1.41-1.71 in the three populations and p values from 0.0018 to 1.6×10 −9 [2] . These results were independently replicated in 2,158 white UK type 2 diabetic subjects, 2,574 geographically matched white control subjects and 388 parent-offspring trios [3] . In this population it was found that the T allele of rs7903146 was the most associated with type 2 diabetes susceptibility (OR=1.36, 95% CI=1.24-1.48 and p=3.6× 10 −10 , MAF=0.31 in control subjects), but that the T allele of rs12255372 was also associated (OR=1.29, 95% CI= 1.18-1.41; p=2.2×10 −6 , MAF=0.30 in control subjects) [3] . These results have also been confirmed by other studies in Finnish and US populations [4, 5] . A study on type 2 diabetes progression suggests that TCF7L2 may be associated with insulin secretion [6] . Therefore, as TCF7L2 is a major gene in type 2 diabetes we can now test if it affects type 1 diabetes susceptibility. We analysed the two SNPs, rs12255372 and rs7903146, in 6,199 white UK type 1 diabetic subjects (5,872 from the Juvenile Diabetes Research Foundation/Wellcome Trust Diabetes and Inflammation Laboratory's Genetic Resource Investigating Diabetes study (http://www-gene.cimr.cam.ac. uk/ucdr//grid.shtml) and 327 from the Oxford Regional Prospective Study [7] ) and 7,596 geographically matched white control subjects (from the 1958 British Birth Cohort [8] ) using TaqMan 5′ nuclease assay (Applied Biosystems, Warrington, Cheshire, UK). All type 1 diabetic subjects were diagnosed under the age of 17 years. Given the reported MAF of 0.30 (in a sample set from the 1958 British Birth Cohort [3] ), our study has 80% power to detect an effect with an OR as low as 1.12 at α=10 −3 . This α level can be considered appropriate assuming that the prior information about common genetic and mechanistic pathways in type 2 diabetes and type 1 diabetes is true. Alternatively, assuming no prior information, on a genomewide level, α=10 −8 , our study has 80% power to detect an effect with an OR as low as 1.19 . In this sample set we obtained a MAF=0.29 for the T alleles of both rs12255372 and rs7903146. The genotype distributions for both of these SNPs were consistent with Hardy-Weinberg equilibrium in the control subjects (p>0.05). We found no evidence for association between TCF7L2 and type 1 diabetes: for rs12255372, OR=0.96 and p=0.17, and for rs7903146, OR=0.99 and p=0.79, for the minor T alleles of both SNPs (Table 1) .
These data do not support a model of a shared major causal pathway in type 2 diabetes and type 1 diabetes. However, as more and more causal variants for common multifactorial diseases are established they will provide a panel of markers that can be used to elucidate the functions and physiology of other diseases. Thus, in this study, we have found that a variant that increases the risk for type 2 diabetes [2] [3] [4] [5] and may affect insulin secretion [6] does not alter susceptibility to the immune-mediated destruction of beta cells in type 1 diabetes to any measurable extent in this British population. 
